p.81 抽出テキスト
122. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart valvular surgery by using coronary computed tomographic angiography versus invasive coronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ jaha.120.019531 123. Opolski MP, Staruch AD, Jakubczyk M, Min James K, Gransar H, Staruch M, et al. CT angiography for the detection of coronary artery stenoses in patients referred for cardiac valve surgery. JACC Cardiovasc Imaging 2016;9:1059–70. https://doi.org/10.1016/j. jcmg.2015.09.028 124. Meijboom Willem B, Mollet Nico R, Van Mieghem Carlos AG, Kluin J, Weustink Annick C, Pugliese F, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery disease in patients referred for cardiac valve surgery. J Am Coll Cardiol 2006;48:1658–65. https://doi.org/10.1016/j.jacc.2006.06.054 125. Gatti M, Gallone G, Poggi V, Bruno F, Serafini A, Depaoli A, et al. Diagnostic accuracy of coronary computed tomography angiography for the evaluation of obstructive coronary artery disease in patients referred for transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur Radiol 2022;32:5189–200. https://doi.org/10. 1007/s00330-022-08603-y 126. Diller GP, Gerwing M, Boroni Grazioli S, De-Torres-Alba F, Radke RM, Vormbrock J, et al. Utility of coronary computed tomography angiography in patients undergoing transcatheter aortic valve implantation: a meta-analysis and meta-regression based on published data from 7458 patients. J Clin Med 2024;13:631. https://doi.org/10. 3390/jcm13020631 127. Kondoleon NP, Layoun H, Spilias N, Sipko J, Kanaan C, Harb S, et al. Effectiveness of pre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc Interv 2023;16:1990–2000. https://doi.org/10.1016/j.jcin.2023.05.030 128. Malebranche D, Hoffner MKM, Huber AT, Cicovic A, Spano G, Bernhard B, et al. Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. BMC Cardiovasc Disord 2022;22:178. https://doi.org/10. 1186/s12872-022-02623-8 129. Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, et al. Routine screening of coronary artery disease with computed tomographic coronary angiography in place of invasive coronary angiography in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv 2015;8:e002025. https://doi.org/10. 1161/circinterventions.114.002025 130. Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, et al. Coronary revascularization in patients undergoing aortic valve replacement for severe aortic stenosis. JACC Cardiovasc Interv 2021;14:2083–96. https://doi.org/10.1016/j.jcin.2021.07.058 131. Miyagawa S, Masai T, Fukuda H, Yamauchi T, Iwakura K, Itoh H, et al. Coronary microcirculatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. Ann Thorac Surg 2009;87:715–9. https://doi.org/10.1016/j.athoracsur.2008.11.078 132. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary artery disease and outcomes of aortic valve replacement for severe aortic stenosis. J Am Coll Cardiol 2013;61:837–48. https://doi.org/10.1016/j.jacc.2012.10.049 133. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, et al. The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg 2015; 149:451–60. https://doi.org/10.1016/j.jtcvs.2014.08.073 134. Lønborg J, Jabbari R, Sabbah M, Veien KT, Niemelä M, Freeman P, et al. PCI in patients undergoing transcatheter aortic-valve implantation. N Engl J Med 2024;391:2189–200. https://doi.org/10.1056/NEJMoa2401513 135. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14: 1965–74. https://doi.org/10.1016/j.jcin.2021.06.041 136. Okuno T, Demirel C, Tomii D, Heg D, Häner J, Siontis GCM, et al. Long-term risk of unplanned percutaneous coronary intervention after transcatheter aortic valve replacement. EuroIntervention 2022;18:797–803. https://doi.org/10.4244/eij-d-22-00342 137. Persits I, Layoun H, Kondoleon NP, Spilias N, Badwan O, Sipko J, et al. Impact of untreated chronic obstructive coronary artery disease on outcomes after transcatheter aortic valve replacement. Eur Heart J 2024;45:1890–900. https://doi.org/10.1093/ eurheartj/ehae019 138. Ogami T, Kliner DE, Toma C, Sanon S, Smith AJC, Serna-Gallegos D, et al. Acute coronary syndrome after transcatheter aortic valve implantation (results from over 40,000 patients). Am J Cardiol 2023;193:126–32. https://doi.org/10.1016/j.amjcard. 2023.02.003 139. Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Incidence and outcomes of acute coronary syndrome after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2020;13:938–50. https://doi.org/10.1016/j.jcin.2019.11.027 140. Yassen M, Moustafa A, Venkataramany B, Schodowski E, Royfman R, Eltahawy E. Clinical outcomes of transcatheter aortic valve replacement with and without percutaneous coronary intervention—an updated meta-analysis and systematic review. Curr Probl Cardiol 2023;48:101980. https://doi.org/10.1016/j.cpcardiol.2023.101980 141. Altibi AM, Ghanem F, Hammad F, Patel J, Song HK, Golwala H, et al. Clinical outcomes of revascularization with percutaneous coronary intervention prior to transcatheter aortic valve replacement: a comprehensive meta-analysis. Curr Probl Cardiol 2022;47: 101339. https://doi.org/10.1016/j.cpcardiol.2022.101339 142. Tomii D, Pilgrim T, Borger MA, De Backer O, Lanz J, Reineke D, et al. Aortic stenosis and coronary artery disease: decision-making between surgical and transcatheter management. Circulation 2024;150:2046–69. https://doi.org/10.1161/circulationaha.124. 070502 143. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. Management of coronary artery disease in patients undergoing transcatheter aortic valve implantation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions in collaboration with the ESC Working Group on Cardiovascular Surgery. EuroIntervention 2023;19:37–52. https://doi.org/ 10.4244/eij-d-22-00958 144. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC Cardiovasc Interv 2020;13:2542–55. https://doi.org/10.1016/j.jcin.2020.07.006 145. Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, et al. Coronary cannulation following TAVR using self-expanding devices with commissural alignment: the RE-ACCESS 2 study. JACC Cardiovasc Interv 2024;17:727–37. https://doi.org/10. 1016/j.jcin.2023.12.015 146. Tang GHL, Amat-Santos IJ, Backer OD, Avvedimento M, Redondo A, Barbanti M, et al. Rationale, definitions, techniques, and outcomes of commissural alignment in TAVR. JACC Cardiovasc Interv 2022;15:1497–518. https://doi.org/10.1016/j.jcin.2022.06.001 147. Campwala SZ, Bansal RC, Wang N, Razzouk A, Pai RG. Factors affecting regression of mitral regurgitation following isolated coronary artery bypass surgery. Eur J Cardiothorac Surg 2005;28:783–7. https://doi.org/10.1016/j.ejcts.2005.10.010 148. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, et al. Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. Circulation 2014;129:2547–56. https://doi. org/10.1161/CIRCULATIONAHA.113.005223 149. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, et al. Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. Eur Heart J 2015;36:2733–41. https://doi.org/10.1093/ eurheartj/ehv343 150. Yousefzai R, Bajaj N, Krishnaswamy A, Goel SS, Agarwal S, Aksoy O, et al. Outcomes of patients with ischemic mitral regurgitation undergoing percutaneous coronary intervention. Am J Cardiol 2014;114:1011–7. https://doi.org/10.1016/j.amjcard.2014.07.012 151. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: 3720–826. https://doi.org/10.1093/eurheartj/ehad191 152. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. Prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed treatment for atrial fibrillation). J Am Heart Assoc 2017;6:e006475. https://doi.org/10. 1161/jaha.117.006475 153. Naser JA, Castrichini M, Ibrahim HH, Scott CG, Lin G, Lee E, et al. Secondary tricuspid regurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm. Eur Heart J 2024;45:2878–90. https://doi.org/10.1093/eurheartj/ehae346 154. Naser JA, Pislaru C, Roslan A, Ciobanu AO, Jouni H, Nkomo VT, et al. Unfavorable tricuspid annulus dynamics: a novel concept to explain development of tricuspid regurgitation in atrial fibrillation. J Am Soc Echocardiogr 2022;35:664–6. https://doi.org/10. 1016/j.echo.2022.02.009 155. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart 2018;104:1292–9. https://doi.org/10.1136/heartjnl-2017-312272 156. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2015;132:624–32. https://doi.org/10. 1161/CIRCULATIONAHA.114.014807 157. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation 2016;134:589–98. https://doi.org/10.1161/CIRCULATIONAHA.115. 020950 158. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2017;69:1372–82. https://doi.org/10.1016/j.jacc.2016.12.031 159. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377–85. https://doi.org/10. 1093/eurheartj/ehu305 160. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 384:2081–91. https://doi.org/10.1056/NEJMoa2101897 ESC Guidelines 4715 Downloaded from academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 07 October 2026